In collaboration with Vistatec, Lya Rebelo, Citeline Commercial Enablement Manager, will be part of a panel discussion sharing insights on the US Food and Drug Administration's updated guidance on Diversity Action Plans.
The US Food and Drug Administration has released long-awaited updated guidance on Diversity Action Plans. This guidance is stronger and very specific in places. How are sponsors, both large and small, responding? What effect will a diversity action plan have on site burden and on patients? How are clinical operations and regulatory affairs teams applying this US-focused guidance in global clinical trials?
Lya Rebelo
Commercial Enablement Manager
A seasoned Global Go-to-Market Manager with 16 years of experience in sales, product management, and marketing, underpinned by a solid background in Organic Chemistry. Adept at managing product marketing from branding to strategy, with extensive international experience interacting with manufacturing sites and sales offices worldwide. Known for a diligent, results-driven approach and exceptional interpersonal skills.